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Background: Pathogenic mutations range from single nucleotide changes to deletions or duplications that
encompass a single exon to several genes. The use of gene-centric high-density array comparative genomic
hybridization (aCGH) has revolutionized the detection of intragenic copy number variations. We implemented an
exon-centric design of high-resolution aCGH to detect single- and multi-exon deletions and duplications in a large
set of genes using the OGT 60 K and 180 K arrays. Here we describe the molecular characterization and breakpoint
mapping of deletions at the smaller end of the detectable range in several genes using aCGH.
Results: The method initially implemented to detect single to multiple exon deletions, was able to detect deletions
much smaller than anticipated. The selected deletions we describe vary in size, ranging from over 2 kb to as small
as 12 base pairs. The smallest of these deletions are only detectable after careful manual review during data
analysis. Suspected deletions smaller than the detection size for which the method was optimized, were rigorously
followed up and confirmed with PCR-based investigations to uncover the true detection size limit of intragenic
deletions with this technology. False-positive deletion calls often demonstrated single nucleotide changes or an
insertion causing lower hybridization of probes demonstrating the sensitivity of aCGH.
Conclusions: With optimizing aCGH design and careful review process, aCGH can uncover intragenic deletions
as small as dozen bases. These data provide insight that will help optimize probe coverage in array design and
illustrate the true assay sensitivity. Mapping of the breakpoints confirms smaller deletions and contributes to the
understanding of the mechanism behind these events. Our knowledge of the mutation spectra of several genes
can be expected to change as previously unrecognized intragenic deletions are uncovered.
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Laboratories that offer diagnostic mutation testing use a
number of methodologies to detect pathogenic chromo-
somal rearrangements, coding sequence aberrations, abnor-
mal methylation patterns, and other biochemical indicators
of genetic disease. These analyses help with diagnoses,
management, carrier testing, and counseling for fam-
ilies affected by an inherited genetic disease. The mu-
tation spectrum of a particular gene guides clinical test* Correspondence: mhegde@emory.edu
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reproduction in any medium, provided the ordevelopment, so that the adapted method promises the
highest yield in detection without compromising sensi-
tivity, specificity, and cost effectiveness. Small muta-
tions, such as nucleotide changes predicted to cause
missense, nonsense, or altered splicing, as well as
frameshifts due to small deletions and duplications of
a few bases, can be detected by sequence analysis. Larger
pathogenic copy number variations (CNVs) are efficiently
detected by high-resolution G-banding, fluorescence in
situ hybridization (FISH), and cytogenomic array com-
parative genomic hybridization (aCGH); however, the size
limitation of these methods is approximately 200–500 kb
or larger.
Recurrent microdeletions and microduplications that
occur between repeat sequences via nonallelic homologousLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CNVs that can easily be detected in diagnostic tests, as the
known breakpoints are amenable to the development of
targeted methods [1,2]. On the other hand, there are CNVs
that primarily represent private non-recurrent familial mu-
tations encompassing several to a single gene. Nonhomolo-
gous end-joining (NHEJ) and microhomology-mediated
break-induced replication (MMBIR) are two mechanisms
responsible for these mutations [3-5]. Chromosomal
microarray is the recommended technique to screen
the entire genome for CNVs, when there is no specific
locus clinically suspected [6].
Gene-targeted diagnostic testing methods can be de-
veloped to screen a specific genomic locus for CNVs,
which is best illustrated by the diagnostic testing for Du-
chenne muscular dystrophy [7]. Pathogenic deletions and
duplications within the DMD gene account for approxi-
mately 65 percent of mutations. Clinical testing for these
mutations has been performed by multiplex standard
PCR (males only) [8,9], quantitative PCR (q-PCR) [10],
and Southern blotting [11], as well as multiple ligation-
dependent probe amplification (MLPA) [12]. These meth-
odologies are laborious and lack sensitivity, particularly
for females, often requiring confirmation testing by a sec-
ond method. To date, the most cost-effective and sensitive
method for the detection of mutations in Duchenne
muscular dystrophy is array-based comparative gen-
omic hybridization (aCGH) [7,13,14].
Several gene-targeted arrays have been developed with
probes concentrated within loci of interest. ExamplesTable 1 Table lists all the cases with intragenic deletions disc
Case Gene Disease: Inheritance Mutation detecte
1 BCKDHB Maple syrup urine disease: AR c.596_597delGT
2 FH Hereditary leiomyomatosis and renal
cell cancer: AD
3 DBT Maple syrup urine disease: AR c.871C > T (p.R291X
4 HPRT1 Lesch-Nyhan syndrome: XL
5 STK11 Peutz-Jeghers syndrome: AD
6 STK11 Peutz-Jeghers syndrome: AD
7 PAH Phenylketonuria: AR c.838G > A (p.E280K
8 EMD Emery-Dreifuss muscular dystrophy: XL
9 DBT Maple syrup urine disease: AR
10 POMT1 Walker-Warburg syndrome AR c.2167dupG
11 SLC9A6 X-linked intellectual disability: XL
12 GALT Galactosemia: AR c.855G > T (p.K285N
& c.844C > G (p.L28
AD: Autosomal Dominant; AR: Autosomal Recessive; XL: X-linked.include an aCGH that targets regions with segmental
duplications and arrays that target only 5–8 specific
genes of interest [15-18]. To be useful in a diagnostic la-
boratory, the design of aCGH has to be optimized to
yield coverage of as many disease-associated genes as
possible without compromising resolution and sensitivity
to detect small intragenic pathogenic CNVs. Roughly,
the detection criteria can be considered single or mul-
tiple exonic CNVs. Detection of pathogenic CNVs at
sub-kilobase resolution have been reported by our la-
boratory and Boone et al. (2010), illustrating the ability
of this technology to identify mutations in patients
with various diseases and syndromes [19,20]. We have
previously reported the development of a custom exon-
centric array designed and implemented at Emory Genet-
ics Laboratory (EGL) [20]. We now report aCGH data
from a set of representative deletions identified with the
use of these arrays during routine laboratory testing that
demonstrate the power and sensitivity of this technology
and illustrate the limit of detection in terms of deletion
size (Table 1).
Results
Univocal detection of deletions larger than 2 kb
Custom-designed gene-targeted aCGH, manufactured
on an Agilent aCGH platform developed by OGT’s Gen-
efficiency service (Oxford Gene Technology, Oxford,
UK), was used for deletion and duplication mutational
analysis for genes that are part of our laboratory’s sequence
analysis repertoire [20]. The Circular Binary Segmentationussed in this manuscript
d with sequencing Mutation detected
with aCGH
Deletion size
Exon 9 deletion ~58 kb
Exons 2–9 deletion ~19 kb
) Exon 5 deletion ~3.7 kb
Exon 5 deletion 2,319 bp
Exon 8 deletion 1,325 bp
Exon 3 deletion 971 bp
) Partial exon 6 deletion 801 bp







False positive: Alu insertion




No deletion False positive: compound
heterozygous missense
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http://www.biomedcentral.com/1471-2156/14/116(CBS) algorithm generated deletion calls using a log2 ratio
of each segment that has a minimum of four probes [21].
Threshold factor for deletions was set as a log2 ratio of
−0.6. Figure 1 shows several examples of aCGH data with
intragenic deletions larger than 2 kb that were easily de-
tected with CBS calls that crossed the −0.6 log2 ratio
threshold. Sequence analysis of the three maple syrup urine
disease (MSUD) genes, BCKDHA, BCKDHB, or DBT, in
two unrelated cases of known biochemical diagnosis of
MSUD detected only one familial mutation each (Table 1)
[22]. One had a known pathogenic mutation in theDeletion  ~ 58 kb 
BCKDHB gene (~239 kb)









Deletion  ~ 3.7 kb 
DBT gene (~63 kb)






Deletion  ~ 19 kb 
FH gene (~22 kb)
Exons:    10 2 1 9 
Figure 1 Examples of large deletions (>2 kb). CytoSure display of aCGH
versus reference Cy3/Cy5 ratio is plotted for each sample. Shown are the m
deletion and duplication calls at log2 ratios of +0.4 and −0.6, respectively (
the right of the CytoSure display mark the −0.6 log2 threshold for deletio
1a top) ~58-kb deletion encompassing exon 9 of the BCKDHB gene. 1a
1a bottom) ~3.7-kb deletion encompassing exon 5 of the DBT gene. 1b
breakpoints of the deletion are shown with vertical red lines. Below the
elements at the deletion locus, followed by an illustration of the breakp
arrows. 1c) Electropherogram of sequenced HPRT1 deleted allele with 69
kind permission of Springer Science + Business Media, as previously pub
Best DH and Swensen JJ, Jan 2012, Chapter 2: Array Comparative Genom
and Hegde M, Figure 2.5, Page 32.BCKDHB gene (c.596_597delGT), whereas the other
family had a DBT gene nonsense mutation (c.871C > T
(p.R291X). Reflex testing for with aCGH yielded the
corresponding second familial mutation; an approxi-
mately 58-kb deletion encompassing exon 9 of the
BCKDHB gene (Figure 1a top) and an approximately
3.7-kb deletion encompassing exon 5 of the DBT gene
were detected in the two above mentioned MSUD
cases (Figure 1a bottom). These examples demonstrate
how conclusive a single exon deletion can be when






HPRT1 gene (~40.5 kb)
















data across genes, with exon locations marked below. The patient
ean of the log2 ratio (thick blue horizontal line) and thresholds for
thin blue horizontal lines), derived from the CBS algorithm. Arrows on
ns. Below the CytoSure display are the corresponding exon tracks.
middle) ~19-kb deletion encompassing exons 2–9 of the FH gene.
) 2,318-bp deletion encompassing exon 5 of the HPRT1 gene. The
CytoSure display are the UCSC RepeatMasker track showing repeat
oint PCR design with location of primers (Fa, Fb, and R) shown as
inserted bases shown. Image in Figure 1c was reproduced, with
lished in Molecular Genetics and Personalized Medicine, edited by
ic Hybridization in Cytogenetics and Molecular Genetics, Askree SH
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tio threshold. Parental samples were tested to confirm
biallelic inheritance in the probands of both families.
Finding two familial mutations in this autosomal reces-
sive disorder made carrier-testing possible for other at-
risk family members.
An additional example presented here is where aCGH
analysis of the FH gene detected a heterozygous deletion
of an intermediate size compared to the two single exon
deletions detected in MSUD cases described above.
However, this 19-kb deletion resulted in a loss of 8 out
of 10 exons of the FH gene. This testing was triggered
due to strong clinical suspicion, in an adult male with a
personal and family history that was highly suggestive of
the autosomal dominant disorder, hereditary leiomyoma-
tosis and renal cell cancer. Sequencing of the relevant
FH gene did not detect a mutation, and aCGH analysis
confirmed the familial (autosomal dominant) FH dele-
tion mutation (Figure 1a middle).
In contrast to the deletions detected in autosomal
genes, deletions in X-linked diseases show high sensitiv-
ity in male probands due to lack of an interfering normal
allele. Lesch-Nyhan syndrome (LNS) is an X-linked recessive
disorder caused by deficiency of the enzyme hypoxanthine
guanine phosphoribosyltransferase (HPRT). A mutation in
the single copy of the HPRT1 gene in a male causes LNS.
[23] A 20-year-old male proband was found to carry a
2.3-kb hemizygous deletion mutation encompassing
exon 5 in the HPRT1 gene (Figure 1b). Subsequently,
his sister was found to carry the familial mutation. We
tested amniocytes from the sister’s pregnancy and de-
termined that the fetus did not inherit the familial de-
letion mutation. Allele-specific PCR was developed
that amplified the deleted allele in the proband and his
sister. Sequence analysis confirmed a 2319-bp deletion
encompassing exon 5 with breakpoints at the exon 5
splice site boundary (Figure 1b, 1c). There was an in-
sertion of 69 bp with no homology to any flanking se-
quence. Upon BLAT query, the inserted bases mapped
to chr5p13.1 (Chr5:40,844,202-40,844,270/hg18) [24]. Data
included in additional information shows the aCGH ana-
lyses on all three family members, the fragment analysis of
the breakpoint PCR, as well as the complete sequence of
the deletion locus (see Additional file 1).
1325-bp and 971-bp deletions in the STK11 gene
Peutz-Jeghers syndrome (PJS) is an autosomal dominant
disorder characterized by intestinal hamartomatous polyps,
an increased risk of certain malignancies, and hyperpig-
mented cutaneous lesions. Mutations in the STK11
gene cause PJS. In two unrelated Caucasian patients who
had clinical presentations consistent with PJS, sequence
analysis of the STK11 gene did not detect a mutation.[25]
Figure 2 shows aCGH data where a deletion callencompassing exon 8 did not cross the −0.6 log2 ratio
threshold set. However, low hybridization of 15 probes
leading to a deletion call of a >1-kb segment triggered
PCR confirmation. Using primers flanking the breakpoint,
the deleted allele was preferentially amplified over the
larger normal allele. Sequencing data confirmed a 1325-bp
deletion with a four-base microhomology at the break-
points in intron 7 and intron 8 (Figure 2a). Fragment
analysis of breakpoint PCR, and the complete sequence
of the deletion locus is included in Additional file 2.
In the second PJS patient, a deletion call encompassing
exon 3 did not cross the −0.6 log2 ratio threshold set,
but was appreciated in manual review (Figure 2b). In
contrast to the previous case, the call was based on 9
probes. However, the patient’s clinical presentation, as
reported by the referring physician, was highly suggest-
ive of PJS syndrome. A 971-bp deletion encompassing
exon 3 of the STK11 gene was subsequently confirmed
and breakpoints mapped with allele-specific PCR and se-
quencing (see additional file 2). Several probes that map
within the deletion did not show hybridization ratios, as
would be expected with the deletion in one allele.
801-bp deletion resulting in partial deletion in the PAH
gene
A sample from a biochemically diagnosed 6-year-old
phenylketonuria (PKU) patient was received for PAH
gene sequencing. One copy of a previously reported mis-
sense mutation, c.838G > A (p.E280K), was detected.[26]
Since a second mutation was not detected, deletion/du-
plication analysis was ordered. A deletion was identified
with four probes partially covering exon 6 and six probes
covering a few hundred bases of immediately flanking
intron 6 sequence (Figure 3a). Four probes over the 5’
end of exon 6 showed a normal hybridization signal. To
confirm the partial deletion of exon 6, breakpoint PCR
was conducted; an 801-bp deletion, with an insertion of
11 bp between the breakpoints in intron 6 and exon 6,
was confirmed. The inserted bases corresponded to the
reverse compliment of the intron 6 breakpoint (figure 3a
bottom). The fragment analysis of the breakpoint PCR,
and the complete sequence of the deletion locus is in-
cluded in Additional file 3. A SINE (Short Interspersed
Element) of the MIRb subfamily maps within the deleted
sequence, 32 bases from the intron 6 breakpoint.
Subsequently, we detected one copy of the same PAH
indel mutation allele, in a presumably unrelated, four-
month-old who was diagnosed via newborn screening
(NBS) to have elevated phenylalanine. PAH gene sequen-
cing identified a c.168 + 1G > A splice donor site muta-
tion (data not shown). Deletion/duplication analysis with
aCGH detected intron6/exon6 deletion that was con-
firmed with the allele-specific PCR and sequencing de-
veloped for the previous patient.
AluY
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Figure 2 Single exon deletions in the STK11 gene. Figure 2 shows the data from two independent aCGH analyses with probes targeting the
entire STK11 gene, and the zoomed-in view of where the deletion was present. CBS-generated deletion call did not cross the −0.6 threshold in
either analysis. The breakpoints of the actual deletion are shown with vertical red lines. Below the CytoSure display are the corresponding
exon tracks. Locations of Alu elements in the region of the deletion are marked. At the bottom is an illustration of the breakpoint PCR design,
with the location of respective primers shown as arrows. Electropherograms of bidirectionally sequenced deleted alleles are shown with sequencing in
the forward direction on top and reverse sequencing below. The four- and three-base pair microhomology at the breakpoints are shown within the
two vertical red lines that demarcate the breakpoints. 2a) 1325-bp deletion encompassing exon 8 of the STK11 gene, with electropherogram
of sequenced STK11 across deleted exon 8. 2b) 971-bp deletion encompassing exon 3 of the STK11 gene, with electropherogram of sequenced
STK11 across deleted exon 3.
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EMD gene
Emery-Dreifuss muscular dystrophy can be inherited in
an autosomal recessive or an X-linked pattern, depend-
ing upon the gene that carries the mutation. Mutations
in EMD cause X-linked Emery-Dreifuss muscular dys-
trophy [27]. We detected a 267-bp deletion encompass-
ing exon 2 of the EMD gene in a 46-year-old male
(Figure 3b). Despite the general criteria set for a mini-
mum of four probes to determine a deletion call, two
probes in a hemizygous condition were sufficient to
prompt further investigation. Breakpoint mapping with
allele-specific PCR revealed that certain probes within the
deleted regions showed normal hybridization (Figure 3b).The fragment analysis of the breakpoint PCR, and the
complete sequence of the deletion locus is included in
Additional file 3.
12-bp intronic deletion in intron 5 of the BCKDHB gene
No mutation was detected by sequence analysis of the
BCKDHA, BCKDHB, and DBT genes in a sample from a
13-year-old patient with a biochemical diagnosis of
MSUD. However, aCGH analysis resulted in one CBS
deletion call within the BCKDHB gene encompassing
the 5’ end of exon 11. In addition, manual review picked
up a possible small deletion at the 5’ end of exon 5 based
on only two probes that map to the sense and antisense
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Figure 3 Deletions with a breakpoint in exons. Figure 3 shows CytoSure display of aCGH data with probes targeting the PAH gene and EMD.
The top panel displays the entire gene view, and the lower panel zooms into the region showing a deletion. Below the CytoSure display are the
corresponding exon tracks, and the UCSC RepeatMasker track showing repeat elements at the deletion locus. Vertical red lines mark the
breakpoints. At the bottom is an illustration of the PCR design. Primers are shown as arrows. 3a) 801-bp deletion encompassing part of exon 6 of
the PAH gene, with electropherogram of sequenced PAH gene across deletion. The breakpoints are shown with vertical red lines. The inserted 11
bases, shown with a green bracket, correspond to the reverse compliment of the bases labeled with a black bracket in the reference sequence
across one of the breakpoints. 3b) 367-bp deletion encompassing part of exon 1 and all of exon 2 of the EMD gene, with electropherogram of
sequenced EMD gene across deletion. The two-base pair microhomology at the breakpoints is shown within the two vertical red lines that
demarcate the breakpoints.
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12-bp deletion (Figure 4). This c.344-4del12 change
is only three bp from the splice acceptor site at the 5’
end of exon 5 and was not detected in the original se-
quence analysis, since the original amplification primers
hybridized to the deleted region, resulting in allelic drop-
out. The sequencing primer had to be placed very close to
the splice site to avoid amplification through an intronic
AT-rich simple repeat region distally. The fragment ana-
lysis of the breakpoint PCR, and the complete sequence of
the deletion locus is included in Additional file 4.
False deletion call due to an insertion mutation in the
POMT1 gene
In some suspected intragenic deletions, further investi-
gation leads to the discovery of an insertion, SNP, or
point mutation causing poor hybridization. For example,
sequence analysis of the POMT1 gene identified a copy
of a c.2167dupG mutation in exon 20 in a patient withWalker-Warburg syndrome (WWS) (data not shown)
[28]. Finding one definite mutation triggered reflex dele-
tion duplication testing. Analysis by aCGH showed four
overlapping probes over exon 3, suggesting a possible
deletion (Figure 5a). Breakpoint PCR and sequence ana-
lysis identified an Alu insertion (c.160_161ins349). The
c.160_161ins349 Alu insertion has been previously re-
ported in a patient with WWS in cis with a c.2203C > T
nucleotide change in exon 20 that was also found in our
patient [29]. By placing the forward primer within the
Alu sequence, the presence of the Alu was confirmed.
The fragment analysis of the breakpoint PCR is included
in Additional file 5.
False-positive deletion call due to hemizygous SNP in the
SLC9A6 gene
A mutation in the X-linked SLC9A6 gene in males re-
sults in intellectual disability, epilepsy, and ataxia, a pheno-
type similar to Angelman syndrome [30]. A possible
DBT
Figure 4 Compound heterozygous deletions in the DBT gene. Figure 4 shows CytoSure display of aCGH data with probes targeting the
entire DBT gene, and zoomed-in views of two deletions: a large, >3.5-kb deletion encompassing the 5’ end of exon 11 is on the left, and a small
12-bp deletion in intron 4, three bases from the intron 4/exon 5 boundary, is on the right. The breakpoints of the small deletion are shown with
vertical red lines. At the bottom is an illustration of the breakpoint PCR design, with the location of primers shown as arrows. Figure 4b shows
the electropherogram indicating the deletion of 12 bases in one allele of the patient. The breakpoints are shown with two vertical red lines.
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a three-year-old male patient was found to be a false-
positive call. Since this is an X-linked gene, a true dele-
tion call is expected to cross well below the threshold.
The deletion call here did fall below the −1, but not to the
degree expected in a hemizygous deletion (Figure 5b). Se-
quencing of exon 9 and flanking intronic sequences re-
vealed a hemizygous single nucleotide polymorphism SNP
(c.1140 + 31C > A; rs2291639). All probes suggesting a
deletion encompass this SNP and result in poor
hybridization on the aCGH. An electropherogram trace
encompassing this SNP is included in Additional file 5.
Low probe hybridization due to compound heterozygous
missense changes in the GALT gene
A five-year-old patient with galactosemia was referred
for GALT gene sequencing [31]. Sequence analysis of
exon 9 of the GALT gene identified one copy of thec.855G > T (p.K285N) mutation and one copy of a
c.844C > G (p.L282V) nucleotide change of unknown
significance, in this individual. Parental testing showed
that these two missense changes (a mutation and a
variant of unknown significance) were in trans. Since
the c.844C > G (p.L282V) nucleotide change has not
been previously reported in a patient with galacto-
semia, aCGH was ordered to rule out the possibility of
a deletion or duplication (Figure 5c). The three probes
highlighted with a red circle overlap both the missense
changes, demonstrating low hybridization that can be
appreciated upon manual review. An electropherogram
trace encompassing these nucleotide changes is in-
cluded in Additional file 5.
Discussion
Custom-designed high-density oligonucleotide arrays
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Figure 5 False deletion calls. Figure 5 shows CytoSure display of three independent sets of aCGH data, where probe hybridizations on three
separate genes resulted in false deletion calls. 5a) Zoomed-in view of the POMT1 gene, where red arrow marks the breakpoint in exon 3, where
an Alu insertion interrupts probe hybridization. Below the CytoSure view is an illustration of the breakpoint PCR design, with the location of
primers shown as arrows. At the bottom is an electropherogram of the allele with the Alu inserted. The 16 bases, duplicated in the two ends of
the inserted element, are shown within two vertical red lines. 5b) Zoomed-in view of the SLC9A6 gene, where red arrow marks the location of a
SNP in intron 9 that is targeted by all the probes that triggered the false deletion call. 5c) The entire GALT gene, with three probes showing
slightly poor hybridization due to compound heterozygous missense changes.
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single and multiple exon deletions and duplications
[7,13,19,20]. The limit of detection in terms of the size
of pathogenic deletions has improved immensely with
the implementation of high-resolution, gene-targeted
aCGH in diagnostic genetics [32,33]. The smallest size
of deletion that analysis software can detect depends
upon the density of probes targeting that sequence and
the criteria set for software-generated calls. For ex-
ample, if four consecutive probes targeted an overlap-
ping sequence, and all four crossed the threshold set to
detect deletions in our method (−0.6 log2 ratio), then a
call could be generated even for deletions smaller than
the length of the probes. As the size of a deletion gets
closer to the limit of detection, the confidence in a call
becomes weaker, and an alternate confirmation is ne-
cessary. Investigating suspicious events with break-
point mapping helped us elucidate the true detection
limit of our gene-targeted aCGH design. Several cases
where software-generated calls did not cross the threshold
nevertheless aroused suspicion upon manual review and
warranted further investigation.
Detection of deletions is highly sensitive in the hemi-
zygous genotype of males with X-linked disease. It isimportant to obtain relevant clinical information, family
history, and any biochemical findings to help interpret
the results of molecular testing; identification of a single
copy of one mutation by gene sequencing for a patient
suspected of an autosomal recessive disorder is also an
indication to investigate any suspicious microarray data.
The smallest deletion we detected with aCGH was the
12-bp intronic deletion in the DBT gene of a child with a
biochemical diagnosis of MSUD (Figure 4). The call made
due to this deletion was only due to the hybridization of
two probes targeting the same 60 bp and was only appre-
ciated upon manual review. The location of these probes
mapped to the sequence that the primer used in sequen-
cing. Therefore, this deletion was not detected by sequen-
cing due to allelic dropout, highlighting the fact that it
was ultimately detected based on high clinical suspicion,
the presence of one copy of another mutation in the same
gene, and keen manual review.
Selection of probes and the density and redundancy in
the coverage in the array design, are critical in the detec-
tion of intragenic CNVs. Not all probes perform equally
well. Both deletions in the STK11 gene described here
failed to generate a call that crossed the threshold set for
deletions (−0.6 log2 ratio). Several probes within the
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(Figure 2 and 3). These data may indicate that the
probes may be prone to non-specific signal and should
be redesigned or removed. However, it is important to
recognize the possibility that sequences within a deleted
region may have translocated to another location within
the gene, or elsewhere in the genome, and consequently
may carry the potential for clinical implications. How-
ever in the STK11 deletions presented, the clinical find-
ings are consistent with the deletions alone.
Most deletions reported here had microhomology of
at least a few bases at the breakpoints. This is consistent
with the replication-based mechanism and break-
induced repair (BIR) mechanism hypothesis for such
events [4,34,35]. Interestingly, in the 801-bp deletion
encompassing part of exon 6 of the PAH gene, there
was an 11-bp insertion that corresponds to the re-
verse compliment of bases along the intron 6 break-
point, demonstrating the involvement of at least two
double-strand breaks in the mechanism resulting in
this deletion (Figure 3). The familial HPRT1 deletion
also had an insertion of 69 bp (Figure 1). In this mutation,
the inserted bases aligned to a region on chromosome 5
(chr5p13.1:40,844,202-40,844,270/hg18) that has no hom-
ology to the locus on the X-linked gene. A second recur-
rent theme at breakpoints is close proximity of SINEs
(Short INterspersed Elements) or other repeat tracks, sug-
gestive of non-allelic homologous recombination.
In spite of the fear that higher probe density generates
more noise in aCGH data, in our experience, the greater
the number of probes within a deleted area generally
helped in its detection. This is true even when there is
redundancy in the probes; for example, the EMD gene
deletion, where the same 60 bp were targeted by probes
complimentary to the two strands. There was a definite
call made by CBS software for the 801-bp PAH gene de-
letion. In contrast, the larger STK11 deletions did not
cross the threshold for the software to generate a call.
This difference is due entirely to probe density, which is
higher for the PAH gene in our array. With sufficient
data, probe performance can be evaluated and array
design modified for optimal sensitivity. Possible dele-
tions that were deemed false positive did demonstrate
how single nucleotide changes could decrease the
hybridization of probes, highlighting the sensitivity of
this technology (Figure 5). In one case, the call gener-
ated did lead to the identification of a pathogenic Alu
insertion. We have found that familiarity with specific
probe performance within a gene helps differentiate
between informative variation and noise.
It is important to remember that oligonucleotide ar-
rays have the same limitations as any method that relies
on hybridization to unique sequence probes. Therefore,
repeat sequences are not targeted, and pseudogenes andhomologs will interfere with assessments. Also, the in-
formation on copy number variation gives no insight on
the orientation or location of insertions, duplications or
rearrangements.
Gene targeted aCGH technology described here is
complementary to diagnostic analyses utilizing next gener-
ation sequencing (NGS) that have been rapidly adopted in
clinical laboratories, especially for genetically heterogenous
diseases where more than one gene can contribute to a
disorder. Several gene panels are being offered by clin-
ical laboratories, for example gene panels for X linked
intellectual disability, cardiomyopathy, neuromuscular
disorders and congenital disorders of glysosylation. De-
tection of small indels from NGS data is still not opti-
mal, and detection of CNVs via NGS cannot be easily
adopted in clinical laboratories since the required low-
ered stringency would introduce a high false positive
variant call rate. Gene targeted can easily fill these gaps
and make the gene panels complete by offering com-
bination of NGS based test and gene targeted arrays to
detect the near complete range of mutations detected
in genes.
Conclusion
We present the examples of pathogenic intragenic dele-
tions ranging from several kilobases to as small as 12
bases, to highlight the limit of detection with high-
density gene-targeted aCGH. Although probe coverage
and performance are critical parameters to consider,
however, there is not a minimum criteria of probe dens-
ity that can be applied across all genomic sequences of
interest. Based on our experiences, rigorous efforts to
detect the smallest of these intragenic CNVs extend be-
yond simple aCGH analysis algorithms. As the size of
deletion gets smaller, the cumulative data from all
encompassing probes is insufficient to make a confident
call. CBS software does allow identification of these
events during manual review, even when the call does
not cross the threshold set for the detection. For detec-
tion of these smaller CNVs, we routinely investigate fur-
ther if one or more of the following criteria are met: a)
the call was generated with at least two entirely non-
overlapping probes, b) the location of the call overlaps
with a primer used in sequencing that may have caused
allelic dropout, c) the disease gene is recessive, with one
mutation within the gene identified, or d) the disease
gene is dominant, with a strong clinical suspicion in the
patient. Ultimately, these data can be used to track indi-
vidual probe performance across samples to improve the
sensitivity of the array. In conclusion, high-density tar-
geted aCGH is a very powerful tool for detection of
intragenic deletions, and the identification of novel
intragenic deletions and duplications will help expand
the known spectrum of disease-associated genes.
Table 2 Table lists primers used in confirming breakpoint
mapping for the cases listed in this manuscript
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Array design
All array data discussed in this manuscript were gener-
ated using the custom-designed EGL_NMD_NBSplus_v1
array. This 4X180K array was developed on the Agilent
Technologies (Santa Clara, CA) aCGH platform using
the Genefficiency service (Oxford Gene Technology (OGT),
Yarnton, Oxford OX5 1PF UK). OGT uses proprietary ink-
jet in situ printer technology (IJISS) developed by Rosetta
InPharmatics (Kirkland, WA) and Agilent Technologies that
allows in situ synthesis of long oligonucleotides. The probes
are ~60 bp in length and annotated against NCBI build 36.1
(UCSC hg18, March 2006). This array has 207 control
probes and 15,028 backbone probes spread in between
regions of interest. 157,448 probes are targeting 261
genes (see Additional file 6).
aCGH protocol
DNA was extracted from whole blood collected in
EDTA (purple-top) collection tubes and from amnio-
cytes received for prenatal testing using the Puregene
DNA extraction kit (Qiagen, Valencia, CA) according to
the manufacturer’s recommendation. aCGH was per-
formed following the manufacturer’s protocol (Agilent
Technologies, Santa Clara, CA). Each patient’s DNA was
spiked with a combination of PCR products (spike-in)
unique to each sample per array. The reference DNA
was used from two pools (male and female) from normal
individuals, run as a same-sex control. DNA was soni-
cated using a Branson Sonifier 450 with cup horn
(Danbury, CT) and visualized on a two-percent agarose
gel prior to labeling, as a quality control measure. Each
patient and reference DNA was labeled with Cy3 and
Cy5 9mer primers, respectively. Purification of labeled
products, hybridization, and post-wash of the array
was carried out according to Agilent’s recommenda-
tion and with their proprietary solutions. Array slides
were scanned with Agilent’s High-Resolution C Scan-
ner and extraction software.
aCGH analysis
CytoSure Interpret software 02002 (OGT) was used for
analysis of array data (referred to as CytoSure). The pro-
gram uses the Circular Binary Segmentation (CBS) algo-
rithm to generate segments along the chromosomes that
have similar copy number relative to reference chromo-
some [21]. Averaging of the segments is with median
value of all segments on a chromosome as the baseline.
Deletion or duplication calls are made using the log2 ra-
tio of each segment that has a minimum of four probes.
Threshold factor for deletions was set as a log2 ratio
of −0.6 that is less stringent than the theoretical log2
score of −1 (heterozygous deletion log2(1/2) = −1; No
change in allele number log2(2/2) = 0; heterozygousduplication log2(3/2) = 0.59). The software uses the
standard deviation of the log2 ratio to calculate a de-
viation log ratio (DLR), which is used as a quality
control check. A DLR of 0.08-0.19 is accepted, 0.20-
0.29 is borderline, and ≥0.30 is rejected. The DLR for
all arrays shown was scored by this scale. Data is ana-
lyzed only for the gene ordered for testing. The data
for others genes is masked and not analyzed.
Breakpoint mapping design
CytoSure segment calls were used to generate minimum
and maximum genomic coordinates of possible aberra-
tions using NCBI build 36.1 (UCSC hg18, March 2006).
The UCSC Genome Browser was used to determine the
composition of the involved DNA [36,37]. We assessed
repeat tracks and segmental duplications, as well as all
annotated SNPs [24,38-43]. Breakpoint mapping by PCR
was used to confirm deletion calls encompassing all or
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were designed using Light Scanner Primer Design soft-
ware (Idaho Technologies Inc, Salt Lake City, UT). Sev-
eral primer sets were designed by walking along the
DNA sequence proximal and distal to the possible CNV.
PCR
All primers were ordered from Integrated DNA Tech-
nologies, Inc. (Coralville, IA). In all PCRs, 50 ng of gen-
omic DNA was amplified in a 50-μl reaction that had a
final composition of 2 U FastStart Taq, 1X FastStart Taq
buffer with MgCl2, and 0.2 mmol/L dNTPs (Roche Ap-
plied Science, Indianapolis, IN), as well as 10 pmol for-
ward and reverse primers (for primers sequences see
Table 2). The PCR cycling had an initial melting at 95°C
for 3 min followed by 40 three-temperature cycles (60 s
at 95°C, 60 s at the lower of the two primer Tms, and
72°C for 1 min). The 40 cycles were followed by a final
extension at 72°C for 7 min, and then held at 4°C. 15 μl
of each PCR product was visualized on a 2% agarose gel
(Fisher Scientific, Waltham, MA). Primers that success-
fully amplified across the breakpoints for cases described
are listed in table 1.
Sequencing
PCR products were purified using the Millipore Ultrafil-
tration PCR purification kit (Millipore, Billerica, MA).
Sequencing reactions (15 μl total) were prepared with
the BD v3.1 sequencing kit (Applied Biosystems, Foster
City, CA). Each PCR product was sequenced bidirection-
ally using the amplification primers. The sequencing re-
action products were purified using a Sephadex cleanup
plate (Edge Biosystems, Gaithersburg, MD) according
to the manufacturer’s instructions. Products were heat-
denatured (5 min at 95°C) and sequenced on a 3730xl
capillary sequencer (Applied Biosystems, Carlsbad, CA).
Sequence analysis was performed using Mutation Sur-
veyor v2.61 software (SoftGenetics, State College, PA).
Additional files
Additional file 1: 2319-bp deletion in the HPRT1 gene.
Additional file 2: 1325-bp deletion in the STK11 gene.
Additional file 3: 801-bp deletion in the PAH gene and 267-bp
deletion in the EMD gene.
Additional file 4: 12-bp deletion in the DBT gene.
Additional file 5: False deletion calls in the POMT1, SLC9A6 and
GALT genes.
Additional file 6: List of genes included in the custom-designed
gene-targeted array.
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